MEDICRIME: The international convention of the Council of Europe as a tool to combat counterfeit medicines

Pharmaceuticals Policy and Law

Volumn 13, Issue 1-2, 2011, Pages 41-55

  Cabezas, M D ^a   Piqueras, A J ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COUNTERFEIT DRUG; ILLICIT DRUG;

ALLOPATHY; ARTICLE; CRIMINAL LAW; DRUG MANUFACTURE; EUROPEAN UNION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM;

EID: 79960135673     PISSN: 13892827     EISSN: 2210495X     Source Type: Journal    
DOI: 10.3233/PPL-2011-0312     Document Type: Article

References (23)

1. WHO. Counterfeit Drugs Kill! IMPACT. International Medical Products Anti-Counterfeiting Task-force. Update May 2008;
2. Gibson L. Drug regulators study global treaty to tackle counterfeit drugs. British Medical Journal, February 28; 328(7438) 2004: 486;
3. Cockburn R, Newton PN, Kyeremateng Agyarko E et al. The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers. Plos Medicine- www.plosmedicine.org, 2(4) 2005: 0302-08; (Pubitemid 40721074)
4. Ibern P. Ante el reto de los medicamentos falsos. ww.correofarmaceutico. com.18/11/2010.
5. Proposal for DIRECTIVE OF THE EUROPEAN PARLIAMENT AND THE COUNCIL amending Directive 2001/83/EC as regards the prevention of the entry into the legal supply chain of medicinal products which are falsified in relation to their identity, history or source. Brussels, 10.12.2008. COM (2008) 668 final.
6. Procedure co-decision of the European Parliament in the first reading 9-02-2011, A7-0148/120.
7. Council of Europe: Convention on the counterfeiting of medical products and similar crimes involving threats to public health.
8. Provisional Edition. CM(2010)30 final. 9 December 2010.
9. CDPC, Council of Europe Convention on the counterfeiting of medical products and similar crimes involving threats to public health, Explanatory Report (2009) 16 fin.
10. Arts. 31 and 32 of the Vienna Convention on the Law on Treaties, 1969.
11. Art 1.1 of the Proposal for a Directive cit. in note.
12. See point 44 in the Explanatory Report cit. in note 3.
13. Recent news reports that a sanction was imposed by the FDA on the pharmaceutical company GLAX-OSMITHKLINEfor distributing adulterated medicinal products alter the accusation of an employee responsible for product quality supervision for the company's products made in a factory in Puerto Rico.
14. A fine of 540 million euros was levied. www.facua.org 28 October 2010.
15. The Spanish Criminal Code distinguishes between adulteration and counterfeiting classifying both actions as crimes against public health (compare Art. 362 Organic Law 10/1995, 23November of the Criminal Code).
16. Bernaus Jose F, Bernaus Carlos G. Adulteracion y falsificacion de medicamentos. Ed. Quorum 2006: 256.
17. Unlike the Framework Decision of the Council of the European Union of 15 March 2001 on the standing of victims in criminal proceedings (2001/220/JAI), OJEU L 82, 22.3.2001, p. 1. Art. 1 does include those suffering economic losses in the concept of victim.
18. Opinion 276 (2010), Draft convention of the Council of Europe on counterfeiting of medical products and similar crimes involving threats to public health: 15.4.
19. in Article 4.fc, after the words "any natural person suffering", add the following, "or liable to suffer".
20. Belesta Segura L. La tentativa inidonea en el Codigo Penal de 1995. Septiember 1999. http://noticias. juridicas.com/articulos/55-Derecho%20Penal/ 199909-t-inidonea.html.
21. As happens in European criminal law generally in accordance with the Framework Decision of the Council of the European Union of 15 March 2001 on the standing of victims in criminal proceedings (2001/220/JAI), OJEU 82, 22.3.2001, p. 1.
22. admittedly, wrongly applied by Member States as shown in the Commission's Report COM(2009) 166 final, 20.4.2009 in conformity with Art. 18 of the Framework Decision cit. of the Council [SEC(2009) 476]).
23. The European Directorate for the Quality of Medicines and Health (EDQM), the European Committee on Pharmaceutical Products and Care (CD-P-PH) and the European Commission on Pharmacopoeia and its consultative group of European Network of Official Laboratories of Control of Medicines (OMCL).